OWLT

Owlet's headline FY2025 net loss of -$39.7M (a 216% YoY 'deterioration') badly misrepresents the business. The MD&A income statement shows the loss is dominated by a non-cash $26.6M common-stock warrant liability mark-to-market swing (vs. a +$9.3M gain in 2024) plus $3.4M net interest. The operating line — what the business actually does — tells the opposite story: operating loss narrowed from -$20.2M to -$8.3M (+59%) on revenue of $105.7M (+35.4%) with a healthy 50.6% gross margin. Revenue has fully recovered and re-accelerated past the 2023 FDA-driven trough ($54.0M → $78.1M → $106M), now diversified across Dream Sock, BabySat, and the newly launched Owlet360 subscription and Dream Sight camera, across 30+ countries. This is a company approaching self-funding, not one falling apart.

Valuation is undemanding for the growth: at $162M market cap the stock trades at ~1.5x sales for a 35%-grower with 50% gross margins and rapidly shrinking operating losses. The balance sheet is no longer distressed — stockholders' equity turned positive at $19.0M (+164%), cash rose 75% to $35.5M, and long-term debt fell to $2.46M. If management sustains ~30% growth and closes the remaining ~$8M operating gap, a re-rating toward 2x sales is plausible.